Table 3.
Multivariate survival analysis.
| OS | DSS | |||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | ||||
| <60 | Reference | Reference | ||
| 60-75 | 2.253 (1.646-3.086) | <0.001* | 1.815 (1.260-2.615) | 0.001* |
| ≥75 | 3.592 (2.639-4.890) | <0.001* | 2.645 (1.863-3.755) | <0.001* |
| Gender | ||||
| Female | Reference | Reference | ||
| Male | 1.336 (1.061-1.681) | 0.014* | 1.340 (1.020-1.759) | 0.036* |
| Primary Site | ||||
| UUT | Reference | Reference | ||
| LUT | 1.248 (0.940-1.657) | 0.125 | 1.183 (0.837-1.671) | 0.341 |
| Surgery | ||||
| Yes | Reference | Reference | ||
| No | 1.301 (1.014-1.670) | 0.039* | 1.539 (1.136-2.084) | 0.005* |
| Radiation | ||||
| Yes | Reference | Reference | ||
| No | 1.315 (0.829-2.087) | 0.245 | 1.521 (0.810-2.858) | 0.192 |
| Chemotherapy | ||||
| Yes | Reference | Reference | ||
| No | 2.031 (1.595-2.585) | <0.001* | 2.405 (1.813-3.191) | <0.001* |
| Ann Arbor Stage | ||||
| Stage I | Reference | Reference | ||
| Stage II | 1.013 (0.736-1.395) | 0.938 | 1.069 (0.723-1.580) | 0.738 |
| Stage III | 1.113 (0.714-1.736) | 0.636 | 1.325 (0.795-2.206) | 0.280 |
| Stage IV | 1.606 (1.202-2.146) | 0.001* | 1.835 (1.298-2.594) | 0.001* |
OS, Overall survival; DSS, disease specific survival; HR, Hazard ratio; CI, Confidence interval; UUT, Upper Urinary Tract; LUT, Lower Urinary Tract; *p < 0.05.